Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Mayumi Lea Anthony

Nurse Practitioner, Adult Health Newark, DE Nurse Practitioner

NPI 1467711952 CMS profile 11167771

774 Christiana Rd Ste 109, Newark, DE 19713

Open in the dashboard

General payments

$16,482

824 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mayumi Lea Anthony of Newark, DE is reported in the CMS Open Payments database as having received $16,482 across 824 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,760 188
2024 General $3,903 185
2023 General $2,884 147
2022 General $2,645 158
2021 General $2,289 146

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mayumi Lea Anthony
  • Nurse Practitioner, Adult Health median
  • Middle half of Nurse Practitioner, Adult Health
  • National median

In program year 2025, general payments to Mayumi Lea Anthony were reported at $4,760. Among 12,696 Nurse Practitioner, Adult Health profiles paid that year, the median was $184 and the middle half received between $59 and $580.

Show as a table
Year Mayumi Lea Anthony Nurse Practitioner, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $2,289 $138 $43–$438 $132
2022 $2,645 $165 $54–$494 $149
2023 $2,884 $178 $61–$549 $160
2024 $3,903 $186 $62–$575 $164
2025 $4,760 $184 $59–$580 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $2,380 138 payments
  2. Abbott Laboratories $1,534 91 payments
  3. Corcept Therapeutics $1,302 51 payments
  4. Insulet Corporation $1,169 35 payments
  5. Amgen Inc. $1,080 51 payments
  6. Sanofi-Aventis U.S. LLC $954 43 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $654 34 payments
  8. Medtronic, Inc. $611 17 payments
  9. Lilly USA, LLC $590 33 payments
  10. AbbVie, Inc. $572 58 payments
  11. Other $5,636 273 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $16,426 821 payments
  2. Education $55 3 payments
Products named General payments · program years 2021–2025
  1. Ozempic $1,638 95 payments
  2. RYBELSUS $1,535 93 payments
  3. Korlym $1,302 51 payments
  4. Omnipod $1,169 35 payments
  5. FreeStyle Libre 3 $1,006 52 payments
  6. Kerendia $654 34 payments
  7. EVENITY $634 30 payments
  8. SYNTHROID $511 54 payments
  9. MINIMED 780G $472 10 payments
  10. Prolia $450 23 payments
  11. Other $9,946 503 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 66 drugs

Part D claims

4,539

Median for Nurse Practitioner: 389

Drug cost

$2,250,871

Median for Nurse Practitioner: $21,885

Branded share of claims

56.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 399 $762,342
Jardiance Empagliflozin Brand 199 $277,990
Trulicity Dulaglutide Brand 90 $149,289
Rybelsus Semaglutide Brand 62 $112,279
Farxiga Dapagliflozin Propanediol Brand 76 $104,530
Mounjaro Tirzepatide Brand 63 $90,278
Tresiba Flextouch U-100 Insulin Degludec Brand 114 $88,488
Humulin R U-500 Kwikpen Insulin Regular, Human Brand 52 $78,801
Januvia Sitagliptin Phosphate Brand 58 $60,698
Tresiba Flextouch U-200 Insulin Degludec Brand 21 $48,236

The 10 drugs with the highest cost, of 66 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Korlym
$493 — —
LEQVIO
$185 — —
TZIELD
$166 — —
Kerendia
$161 26 —
RYBELSUS
$157 62 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

824 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Adult Health in Delaware

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record